ReviewClinical reviews in allergy & immunology
Beta2-agonists and exercise-induced asthma.
Review in Clinical reviews in allergy & immunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Beta₂-agonists for exercise-induced asthma.The Cochrane database of systematic reviews · 2013Pooled it
- A standard, single dose of inhaled terbutaline attenuates hyperpnea-induced bronchoconstriction and mast cell activation in athletes.Journal of applied physiology (Bethesda, Md. : 1985) · 2016Trial
- Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide.American journal of respiratory and critical care medicine · 2013Trial
- Cromoglycate, reproterol, or both--what's best for exercise-induced asthma?Sleep & breathing = Schlaf & Atmung · 2012Trial
- An evaluation of levalbuterol HFA in the prevention of exercise-induced bronchospasm.The Journal of asthma : official journal of the Association for the Care of Asthma · 2007Trial
- The impact of a heat and moisture exchange mask on respiratory symptoms and airway response to exercise in asthma.ERJ open research · 2020Article
- Understanding reliever overuse in patients purchasing over-the-counter short-acting betaBMJ open · 2019Observational
- Exercise-Induced Bronchospasm and Allergy.Frontiers in pediatrics · 2017Review
- Exercise and asthma: an overview.European clinical respiratory journal · 2015Article
- Exercise-induced bronchoconstriction: new evidence in pathogenesis, diagnosis and treatment.Asthma research and practice · 2015Review
- Beta2-agonists for exercise-induced asthma.Paediatrics & child health · 2014Article
- Pediatric exercise-induced bronchoconstriction: contemporary developments in epidemiology, pathogenesis, presentation, diagnosis, and therapy.Current allergy and asthma reports · 2013Review
- Practical approach to exercise-induced bronchoconstriction in athletes.Primary care respiratory journal : journal of the General Practice Airways Group · 2013Article
- Special considerations for adolescent athletic and asthmatic patients.Open access journal of sports medicine · 2013Review
- Asthma outcomes: pulmonary physiology.The Journal of allergy and clinical immunology · 2012Review
- Airway hyperresponsiveness in asthma: mechanisms, clinical significance, and treatment.Frontiers in physiology · 2012Article
- Approach to the diagnosis and management of suspected exercise-induced bronchoconstriction by primary care physicians.BMC pulmonary medicine · 2009Article
- Exercise-Induced Asthma Symptoms and Nighttime Asthma: Are They Similar to AHR?Journal of allergy · 2009Article
- Cutting edge issues in autoimmunity.Clinical reviews in allergy & immunology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Beta2-agonists taken immediately before exercise provide significant protection against exercise- induced asthma (EIA) in most patients. However, when they are taken daily, there are some negative aspects regarding severity, control, and recovery from EIA. First, there is a significant minority (15-20%) of asthmatics whose EIA is not prevented by beta2-agonists, even when inhaled corticosteroids are used concomitantly. Second, with daily use, there is a decline in duration of the protective effect of long-acting beta2-agonists. Third, if breakthrough EIA occurs, recovery of lung function is slower in response to a beta2-agonist, and additional doses are often required to achieve pre-exercise values. If a person who takes a beta2-agonist daily experiences problems with exercise, then the physician should consider changing the treatment regimen to achieve better control of EIA. These problems likely result from desensitization of the beta2-receptor on the mast cell, which enhances mediator release, and on the bronchial smooth muscle, which enhances the bronchoconstrictor response and delays recovery from EIA. These effects are reversed within 72 h after cessation of a beta2-agonists. The important clinical question is: Are we actually compromising the beneficial effects of beta2-agonists on the prevention and recovery from EIA by prescribing them daily? Patients with EIA need to ensure that their doses of inhaled corticosteroid or other anti-inflammatory therapy are optimized so that, if necessary, a beta2-agonist can be used intermittently as prophylactic medication with greater confidence in the outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.